AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B December 9, 2024
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa December 2, 2024
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy October 29, 2024
AAVantgarde Announces First Patient Dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 Study for Retinitis Pigmentosa Related to USH1B September 16, 2024
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B May 3, 2024
AAVantgarde Presents Positive Preclinical Data in Large Animal Models from its Stargardt Disease Program in an Oral Presentation at the ASGCT 2024 Annual Meeting April 23, 2024
